Cigna's (NYSE:CI) pharmacy benefit manager, Evernorth Health Services, announced on Thursday plans to launch a biosimilar to Johnson & Johnson's (NYSE:JNJ) blockbuster arthritis therapy Stelara ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

The report noted that J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which J&J ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...